Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation

• المؤلفون الرئيسيون: Bárbara Lima (مؤلف), Miguel Henriques Abreu (مؤلف), Susana Sousa (مؤلف), Carla Bartosch (مؤلف), Deolinda Pereira (مؤلف)
• التنسيق: كتاب
• منشور في: Elsevier, 2022-04-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Low-grade serous ovarian cancer (LGSOC) is now considered a different entity from high-grade serous ovarian cancer. The chemoresistance inherent to this type of ovarian cancer narrows the therapeutic options, especially in the recurrent setting. It is thought that the mitogen-activated protein kinas...